Discovery of Eucalyptin C, derived from the fruits of Eucalyptus globulus Labill., as a novel selective PI3Kγ inhibitor for immunosuppressive treatment

被引:0
|
作者
HU Xiao-Long [1 ]
SHEN Wei [1 ]
WANG Rong [1 ]
LONG Huan [1 ]
WANG Quan [1 ]
FENG Jia-Hao [1 ]
PHAM Thi-Anh [1 ]
XIONG Fei [2 ]
YE Wen-Cai [3 ]
WANG Hao [1 ]
机构
[1] State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
[2] State Key Laboratory of Bioelectronics, Jiangsu Laboratory for Biomaterials and Devices, Southeast University
[3] Institute of Traditional Chinese Medicine and Natural Products, Jinan University
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
D O I
暂无
中图分类号
R285 [中药药理学];
学科分类号
1008 ;
摘要
The fruits of Eucalyptus globulus Labill. are known to have a plenty of medicinal properties, such as anti-tumor, antiinflammatory, and immunosuppressive activity. Our previous study found that the phloroglucinol-sesquiterpene adducts in the fruits of E. globulus were immunosuppressive active constituents, especially Eucalyptin C(EuC). Phosphoinositide 3-kinases-γ(PI3 Kγ) plays a pivotal role in T cell mediated excessive immune responses. In this study, EuC was first discovered to be a novel selective PI3 Kγ inhibitor with an IC50 value of 0.9 μmol·L-1and selectivity over 40-fold towards the other PI3 K isoforms. Molecular docking, molecular dynamics simulation, and cellular thermal shift assay showed that EuC bound to PI3 Kγ. Furthermore, EuC suppressed the downstream of PI3 Kγ to induce the apoptosis and inhibit the activation of primary spleen cells derived from allergic contact dermatitis mice. This work highlights the role of the fruits of E. globulus as a source of bioactive plant with immunosuppressive activity.
引用
收藏
页码:844 / 855
页数:12
相关论文
共 50 条
  • [41] Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode
    Down, Kenneth
    Amour, Augustin
    Anderson, Niall A.
    Barton, Nick
    Campos, Sebastien
    Cannons, Edward P.
    Clissold, Cole
    Convery, Maire A.
    Coward, John J.
    Doyle, Kevin
    Duempelfeld, Birgit
    Edwards, Christopher D.
    Goldsmith, Michael D.
    Krause, Jana
    Mallett, David N.
    McGonagle, Grant A.
    Patel, Vipulkumar K.
    Rowedder, James
    Rowland, Paul
    Sharpe, Andrew
    Sriskantharajah, Srividya
    Thomas, Daniel A.
    Thomson, Douglas W.
    Uddin, Sorif
    Hamblin, J. Nicole
    Hessel, Edith M.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (18) : 13780 - 13792
  • [42] Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
    Ohwada, Jun
    Ebiike, Hirosato
    Kawada, Hatsuo
    Tsukazaki, Masao
    Nakamura, Mitsuaki
    Miyazaki, Takuya
    Morikami, Kenji
    Yoshinari, Kiyoshi
    Yoshida, Miyuki
    Kondoh, Osamu
    Kuramoto, Shino
    Ogawa, Kotaro
    Aoki, Yuko
    Shimma, Nobuo
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (06) : 1767 - 1772
  • [43] Discovery of a novel photoswitchable PI3K inhibitor toward optically-controlled anticancer activity
    Zhang, Yan
    Peng, Shouguo
    Lin, Songwen
    Ji, Ming
    Du, Tingting
    Chen, Xiaoguang
    Xu, Heng
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 72
  • [44] Discovery of CT365, a highly potent inhibitor of PI3K and mTOR, for cancer treatment
    Xi, Ning
    Wu, Yanjun
    Wang, Tingjin
    Wang, Heng
    Li, Zhiyong
    Meng, Qingwei
    Li, Jing
    Wang, Zhaohe
    Zhang, Yingjun
    [J]. CANCER RESEARCH, 2015, 75
  • [45] Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
    Zhu, Jingyu
    Ke, Ke
    Xu, Lei
    Jin, Jian
    [J]. RSC ADVANCES, 2019, 9 (35) : 20207 - 20215
  • [46] Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies
    Jiang, Shuwen
    Li, Xiangkun
    Xue, Weifang
    Xia, Sumei
    Wang, Jian
    Sai, Yang
    Dai, Guangxiu
    Su, Weiguo
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [47] A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
    Sun, Xin
    Yang, Yang
    Xia, Lulu
    Wang, Shiyu
    Fu, Yuxing
    Zhu, Yuxuan
    Xu, Shan
    Zhu, Wufu
    Zhu, Wufu
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [48] Discovery of a novel series of potent and selective Phosphatidylinositol-3-Kinase delta (PI3Kδ) inhibitors for the treatment of inflammatory and autoimmune diseases
    Aguilar, Nuria
    Carles Fernandez, Joan
    Hernandez, Begona
    Carrascal, Marta
    Nino, Patricia
    Lopez, Alba
    Vazquez, Laura
    Lozoya, Estrella
    Maldonado, Monica
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [49] Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer
    Yang, Chengbin
    Wang, Menghui
    Gong, Yimin
    Deng, Mingli
    Ling, Yun
    Li, Qingquan
    Wang, Jianxin
    Zhou, Yaming
    [J]. BIOORGANIC CHEMISTRY, 2023, 140
  • [50] INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer
    Jessen, Katayoun A.
    Kessler, Linda
    Kucharski, Jeff
    Guo, Xin
    Staunton, Jocelyn
    Elia, Marikka
    Janes, Matthew
    Lan, Lucy
    Wang, Shunyou
    Stewart, Josh
    Darjania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Michael
    Ren, Pingda
    Fruman, David
    Rommel, Christian
    Liu, Yi
    [J]. CANCER RESEARCH, 2011, 71